Ideaya Biosciences Inc (NASDAQ: IDYA) Is Worth A Shot If You’re A Risk-Capital Investor

In the last trading session, 2.13 million Ideaya Biosciences Inc (NASDAQ:IDYA) shares changed hands as the company’s beta touched 0.80. With the company’s per share price at $37.71 changed hands at -$0.74 or -1.92% during last session, the market valuation stood at $2.85B. IDYA’s last price was a discount, traded about -26.6% off its 52-week high of $47.74. The share price had its 52-week low at $20.90, which suggests the last value was 44.58% up since then. When we look at Ideaya Biosciences Inc’s average trading volume, we note the 3-month average coming to 693.70K.

Ideaya Biosciences Inc (NASDAQ:IDYA) trade information

Instantly IDYA was in red as seen at the end of in last trading. With action -6.89%, the performance over the past five days has been red. The drop to weekly highs of 42.20 subtracted -1.92% to the stock’s daily price. The company’s shares are showing year-to-date upside of 5.99%, with the 5-day performance at -6.89% in the red. However, in the 30-day time frame, Ideaya Biosciences Inc (NASDAQ:IDYA) is -2.36% down.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Ideaya Biosciences Inc (IDYA) estimates and forecasts

Data shows that the Ideaya Biosciences Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 19.34% over the past 6 months, a -20.41% in annual growth rate that is considerably lower than the industry average of 15.30%. Year-over-year growth is forecast to reach -43.00% down from the last financial year.

Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 4.31M. 10 analysts are of the opinion that Ideaya Biosciences Inc’s revenue for the current quarter will be 4.5M. The estimates for the next quarter sales put growth at -44.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -2.95%. The 2024 estimates are for Ideaya Biosciences Inc earnings to decrease by -17.65%.

IDYA Dividends

Ideaya Biosciences Inc is expected to release its next quarterly earnings report in June.